The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2014Neuromelanin in Circulating Phagocytes May Reveal Early Neurodegeneration in Parkinson's Disease Supplement
Promising Outcomes of Original Grant:
The pigment neuromelanin is specifically found in the nerves destroyed by Parkinson’s disease. We developed a way to measure neuromelanin and then looked for... -
Research Grant, 2014Phase IB Follow-up Study to Assess Boost Immunization with AFFITOPE® PD01A
Study Rationale:
PD01A is an alpha-synuclein-targeting vaccine. Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease, and its reduction is expected... -
Access to Data and Biospecimens, 2014Diurnal Fluctuations in Secreted Inflammatory Factors
Study Rationale/Hypothesis:
The goal of this study is to determine the extent to which inflammatory factors in biofluids (cerebrospinal fluid, plasma and serum) vary throughout the course of a given... -
Access to Data and Biospecimens, 201414-3-3 Phosphorylation as a Biomarker for Parkinson’s Disease
Study Rationale:
Disruption of 14-3-3 proteins is implicated in PD, and we have previously demonstrated that increasing 14-3-3 expression is protective in PD models. Recently, we... -
LRRK2 Challenge, 2014Mitochondrial Homeostasis and LRRK2 Parkinsonism: Novel Neuroprotection Targets
Objective/Rationale:
The genes related to familial forms of Parkinson’s disease (PD) have been associated with alterations of normal mitochondrial integrity and function. Little is known... -
Rapid Response Innovation Awards, 2014Disease-modifying Potential of Nortriptyline in Parkinson’s Disease
Objective/Rationale:
Aggregation of the protein alpha-synuclein is toxic to dopamine neurons. Therefore, a compound that reduces or clears this protein could be a viable therapeutic option...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.